CORDIS
EU research results

CORDIS

English EN
NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIGHT RESISTANCE MECHANISMS

NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIGHT RESISTANCE MECHANISMS

Objective

The worldwide spread of antibiotic-resistant microorganisms can be viewed as an ecological consequence of the systematic use of antimicrobial agents. Resistant bacteria prevail in healthcare environments where antibiotic selective pressure is intensive. Novel therapeutic approaches are urgently required to deliver the well-documented existing drugs in an optimized fashion to: i) protect them toward degradation; ii) increase their bioavailability; iii) reduce toxic side effects; iv) increase patient compliance and iv) reduce treatment duration and related costs. In this sense, nanocarriers based on cyclodextrins (CDs) are particularly appealing for the delivery of antibiotics. This approach is of main interest for tuberculosis (TB), infections related to Salmonella Typhimurium, Staphyloccocus aureus and for species most frequently implicated in hospital infections such as enteric gram-negative rods. We will design and characterize CD-based nanocarriers, test their ability to encapsulate drugs, study their efficacy in vitro on bacteria and infected cells. The best formulation will be tested in vivo and scaled up. The objectives of the CycloN Hit project are to take full advantage of nanotechnology and of the high level interdisciplinary expertise of the partners to efficiently encapsulate and protect antibiotics in nanocarriers to combat resistant bacteria, and study the mechanisms in biological systems using state-of-the art techniques. This will be accomplished through a strong and demanding training program for 11 Early Stage and 5 young Experienced Researchers which will gather interdisciplinary expertise of 11 Full partners and 6 Associated partners, of which 7 are SMEs. Using the most recent advances in the nanomedicine field, the final goal of the CycloN Hit project is to bring to the preclinical studies an antibiotic formulation for the treatment of TB and more tailored alternative therapeutic approaches for other resistant microorganisms.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Address

Rue Michel Ange 3
75794 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 259 170

Administrative Contact

Véronique Debisschop (Ms.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Greece

EU Contribution

€ 366 969,24

UNIVERSIDAD DE CASTILLA - LA MANCHA

Spain

EU Contribution

€ 234 931,62

UNIVERSIDAD DE ALMERIA

Spain

EU Contribution

€ 234 931,62

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 382 894,98

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 249 087,96

HASKOLI ISLANDS

Iceland

EU Contribution

€ 230 637

HELLENIC PASTEUR INSTITUTE

Greece

EU Contribution

€ 230 318,88

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 268 175,16

CYCLOLAB CIKLODEXTRIN KUTATO-FEJLES

Hungary

EU Contribution

€ 205 505,52

NANOLOGICA AB

Sweden

EU Contribution

€ 232 272,04

Project information

Grant agreement ID: 608407

Status

Closed project

  • Start date

    1 March 2014

  • End date

    28 February 2018

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 3 894 894,02

  • EU contribution

    € 3 894 894,02

Coordinated by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

This project is featured in...